You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

PROHANCE Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


Which patents cover Prohance, and when can generic versions of Prohance launch?

Prohance is a drug marketed by Bracco and is included in two NDAs.

The generic ingredient in PROHANCE is gadoteridol. One supplier is listed for this compound. Additional details are available on the gadoteridol profile page.

Drug patent expirations by year for PROHANCE
Drug Prices for PROHANCE

See drug prices for PROHANCE

Recent Clinical Trials for PROHANCE

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
University of Alabama at BirminghamEarly Phase 1
University of Alabama at BirminghamPhase 1
Bayer AG (Sponsor)Phase 4

See all PROHANCE clinical trials

Pharmacology for PROHANCE
Anatomical Therapeutic Chemical (ATC) Classes for PROHANCE

US Patents and Regulatory Information for PROHANCE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Bracco PROHANCE gadoteridol INJECTABLE;INJECTION 020131-001 Nov 16, 1992 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Bracco PROHANCE MULTIPACK gadoteridol INJECTABLE;INJECTION 021489-001 Oct 9, 2003 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for PROHANCE

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Bracco PROHANCE gadoteridol INJECTABLE;INJECTION 020131-001 Nov 16, 1992 ⤷  Try a Trial ⤷  Try a Trial
Bracco PROHANCE gadoteridol INJECTABLE;INJECTION 020131-001 Nov 16, 1992 ⤷  Try a Trial ⤷  Try a Trial
Bracco PROHANCE gadoteridol INJECTABLE;INJECTION 020131-001 Nov 16, 1992 ⤷  Try a Trial ⤷  Try a Trial
Bracco PROHANCE gadoteridol INJECTABLE;INJECTION 020131-001 Nov 16, 1992 ⤷  Try a Trial ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

International Patents for PROHANCE

See the table below for patents covering PROHANCE around the world.

Country Patent Number Title Estimated Expiration
Germany 3855451 ⤷  Try a Trial
Germany 3772785 ⤷  Try a Trial
European Patent Office 0232751 1-SUBSTITUTED-4,7,10-TRISCARBOXYMETHYL-1,4,7,10-TETRAAZACYCLODODECANE AND ANALOGS ⤷  Try a Trial
European Patent Office 0292689 1,4,7-Triscarboxyméthyl-1,4,7,10-tétraazacyclododécane substitué et analogues (Substituted 1,4,7-triscarboxymethyl-1,4,7,10-tetraazacyclo-dodecane and analogs) ⤷  Try a Trial
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.